In this month’s Connection newsletter:
- Navigate to curated resources on blood cancers for blood cancer awareness month.
- Familiarize yourself with the information available in your FormularyDecisions Inbox. It’s more than just a message bank.
- Explore the current MyInsights Program feedback opportunities.
- Mark your calendars for an exclusive FormularyDecisions networking event at the upcoming NASP Annual Meeting in Nashville and AMCP Nexus in Las Vegas.
- Register for the upcoming AMCP PIE Webinar on Radicular Leg Pain Associated With Lumbar Disc Herniation.
Blood Cancer Awareness Month
September is blood cancer awareness month. 1.6 million people in the US are currently living with or in remission from blood cancers.1 The National Cancer Institute estimates there will be 62,770 new cases2 of leukemia, 80,620 new cases of non-Hodgkin lymphoma, and 8,570 new cases3 of Hodgkin’s lymphoma in 2024.4
Leverage the different types of FormularyDecisions resources below to familiarize yourself with the evidence available on blood cancers
Your FormularyDecisions Inbox: More Than a Message Bank
Did you know that your FormularyDecisions inbox provides you with more than just notifications? See below for descriptions of the different types of information you can monitor and access through your FormularyDecisions inbox.
Notifications:
Check your notification history for automated updates on eDossiers. A red dot on the envelope icon at the top right of your screen signals an unread notification.My Webinar:
View a list of all your registered webinars, join webinars up to 15 minutes before they start, and watch recordings on-demand.eDossier Requests:
Track the status of your eDossier requests, which specify the included product and disease state(s).Other Requests:
Monitor the status of your requests for information outside of the eDossier. A record of the inquiry you submitted in the free text box of the Submit eRequest tool is available for your reference.Resource Center File Requests:
Keep tabs on access requests for Resource Center files. Use the Contact Us button for assistance with following up with a biopharma company regarding pending requests.Email report:
Choose this option to receive new notifications via email daily, weekly, or monthly.
MyInsights Program Survey Opportunities Available
Product surveys are an important way to share your insights with biopharma companies. Not only does your feedback communicate specific content requests to biopharma companies (eg, comparative effectiveness analysis, real-world evidence) so that they are more likely to post helpful files to FormularyDecisions, but it also helps biopharma companies identify potential evidence gaps that can be filled over time.
Log into FormularyDecisions to view all survey and feedback opportunities available. Earn points for completing surveys that can be redeemed in the form of gift cards and/or donated to a charity.
Below are links to the Product Page for surveys that are at the top of the list of all available surveys when you sort by “Most Recent” on FormularyDecisions.
Status |
Product page with survey opportunities |
|
Pre-approvala |
|
|
FDA-approvedb |
FILSUVEZ® (birch triterpenes topical gel)5 |
Don’t forget to also check out the following survey opportunities that may be leaving soon.
Status |
Product page with survey opportunities |
|
FDA-approvedb |
AKEEGA® (niraparib and abiraterone acetate)10 |
Connecting at Conferences
NASP Annual Meeting in Nashville, Tennessee
As we gather in the vibrant heart of Music City, our networking session is the perfect opportunity to mingle with your colleagues. Enjoy the warm Southern hospitality as you build relationships and share ideas in a relaxed atmosphere.
Session: Snack & Learn: Networking in Nashville with FormularyDecisions
Date: Tuesday, October 8, 2024
Time: 2:00pm to 3:00pm CT
Location: Gaylord Opryland Resort & Convention Center, Room: Cheekwood G
If you have questions, please contact us at Support@FormularyDecisions.com.
Session: Snack & Learn: Networking in Nashville with FormularyDecisions
Date: Tuesday, October 8, 2024
Time: 2:00pm to 3:00pm CT
Location: Gaylord Opryland Resort & Convention Center, Room: Cheekwood G
Space is limited. Please RSVP by October 1.
If you have questions, please contact us at Support@FormularyDecisions.com.
AMCP Nexus in Las Vegas, Nevada
Join us for afternoon tea and sandwiches while you learn more about how your colleagues are leveraging FormularyDecisions in their product review process.
Session: Afternoon tea with FormularyDecisions, an exclusive networking event
Date: Wednesday, October 16, 2024
Time: 1:30pm to 2:30pm PT
Location: MGM Grand Hotel and Convention Center, Room 204
If you have questions, please contact us at Support@FormularyDecisions.com.
Session: Afternoon tea with FormularyDecisions, an exclusive networking event
Date: Wednesday, October 16, 2024
Time: 1:30pm to 2:30pm PT
Location: MGM Grand Hotel and Convention Center, Room 204
Space is limited. Please RSVP by October 8.
If you have questions, please contact us at Support@FormularyDecisions.com.
Upcoming Webinar
AMCP PIE Webinar
Session: Preapproval Information Exchange in Radicular Leg Pain Associated With Lumbar Disc Herniation
Date: Thursday, October 24, 2024
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
Time: 2:00-3:00pm ET
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
This PIE webinar is sponsored by Ferring Pharmaceuticals Inc. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision makers and biopharma companies.
Click below for webinar details and to register:
References:
1. The Leukemia & Lymphoma Society. Count on LLS this Blood Cancer Awareness Month. September 1, 2023. Accessed August 26, 2024. https://www.lls.org/blog/count-lls-blood-cancer-awareness-month
2. National Cancer Institute. Cancer Stat Facts: Leukemia. Accessed August 26, 2024. https://seer.cancer.gov/statfacts/html/leuks.html
3. National Cancer Institute. Cancer Stat Facts: Non-Hodgkin lymphoma. Accessed August 27, 2024. https://seer.cancer.gov/statfacts/html/nhl.html
4. National Cancer Institute. Cancer Stat Facts: Hodgkin lymphoma. Accessed August 27, 2024. https://seer.cancer.gov/statfacts/html/hodg.html
5. Filsuvez prescribing information. Chiesi USA, Inc.; 2024. https://resources.chiesiusa.com/Filsuvez/FILSUVEZ_PI.pdf
6. Rybrevant prescribing information. Janssen Pharmaceuticals, Inc.; 2024. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf
7. Turalio prescribing information. Daiichi Sankyo, Inc.; 2023. https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Turalio&inline=true
8. Skyclarys prescribing information. Reata Pharmaceuticals, Inc.; 2024. https://www.skyclarys.com/docs/skyclarys_us_prescribing_information/
9. Vanflyta prescribing information. Daiichi Sankyo, Inc.; 2024. https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Vanflyta&inline=true
10. Akeega prescribing information. Janssen Biotech, Inc.; 2024. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/AKEEGA-pi.pdf
11. Hemgenix prescribing information. CSL Behring LLC; 2022. https://labeling.cslbehring.com/PI/US/Hemgenix/EN/Hemgenix-Prescribing-Information.pdf
12. Jardiance prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s040lbl.pdf
13. Keytruda prescribing information. Merck & Co., Inc.; 2024. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
14. Litfulo prescribing information. Pfizer Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
15. Talzenna prescribing information. Pfizer Inc.; 2024. https://labeling.pfizer.com/ShowLabeling.aspx?id=11046
16. Veltassa prescribing information. Vifor Pharma, Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205739s037lbl.pdf
17. Xeljanz prescribing information. Pfizer Inc.; 2024. https://labeling.pfizer.com/ShowLabeling.aspx?id=959
18. Zavzpret prescribing information. Pfizer Inc.; 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf
a The material is being shared to inform you of the availability of information on FormularyDecisions. In providing this information, FormularyDecisions is not promoting any products mentioned, making claims about risks or benefits, or otherwise recommending any product in general or for any patient or formulary. For complete information about the indications, risks, and benefits of any product, please consult appropriate clinical and safety information, including the complete product label and important safety information. All prescribing decisions and/or coverage decisions should be made independently by individuals with appropriate experience in reliance on their independent judgement.
b The products listed are in the clinical evaluation stage and have not been approved for use by the FDA. The safety and efficacy of these products have not been established. FormularyDecisions is providing this information to alert you to the status of this product and is not promoting this product generally or otherwise recommending this product for use in the treatment of any disease or inclusion on any formulary for which it has not yet been approved. Any questions about such products must be directed to the biopharma companies. The availability of this product information follows the guidance outlined in the Pre-approval Information Exchange Act of 2022 (Section 810 of H.R. 7667).
FormularyDecisions is owned and operated by Xcenda L.L.C., which is a subsidiary of Cencora, a global pharmaceutical sourcing and distribution services company.
The contents of this communication are non-promotional and intended exclusively for healthcare decision-makers, formulary committees, and other similar entities responsible for selecting healthcare products for coverage or reimbursement. Do not forward this communication. FormularyDecisions strongly encourages our members to review all available information about a particular product, including but not limited to the product label, and to rely on their experience and expertise in making decisions about coverage or prescribing.